The Canadian Alliance of Pediatric Rheumatology Investigators National Juvenile Idiopathic Arthritis Registry View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2026

ABSTRACT

Juvenile Idiopathic Arthritis (JIA) is a disorder of unknown cause characterized by chronic inflammation of the joints and other organs. It affects about 1 in a 1000 Canadian children and if untreated it can produce lifelong disability. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) includes most pediatric rheumatologists in Canada. They have successfully collaborated for the past 10 years producing groundbreaking research on the modern course and outcomes of JIA. CAPRI proposes an ongoing universal registry of Canadian children with JIA that will collect longitudinal data on disease course, outcomes and adverse events to inform healthcare decisions and to gain new insights into the disease and its treatment. Detailed Description 1. BACKGROUND JIA includes all chronic arthritis of unknown cause starting before the age of 16. JIA is the most common rheumatic disease of childhood, affecting approximately 1 in 1,000 Canadian children. Despite trends to more favorable outcomes, JIA continues to have disabling sequelae that reduce mobility, quality of life and future productivity, affecting the child, their families and society as a whole. After a diagnosis of JIA, families have many questions about the prognosis of their child, treatments that may be required and their potential side-effects. Despite numerous studies, our ability to answer these questions remains limited. International League of Associations for Rheumatology (ILAR) criteria classify children with JIA into seven categories based on clinical manifestations and laboratory tests. Current practice recommendations propose use of medications tailored according to JIA category or according to treatment groups defined by number of joints affected and features of poor prognosis. In general, initial treatment with intraarticular corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for JIA affecting a few joints; while methotrexate and biologic agents are recommended when many joints are affected and for children with features of poor prognosis. CAPRI is the collaborative network of all pediatric rheumatology investigators across Canada, with an outstanding track record of successful collaboration in a number of research projects. Since 2005 CAPRI investigators have worked on a project called ReACCH-Out, a team grant funded by the Canadian Institutes of Health Research (CIHR) to study the impact of arthritis on Canadian children. CAPRI developed a robust web-based longitudinal data base and enrolled 1,500 newly diagnosed children with JIA during a five year period. This study has resulted in one of the largest longitudinal JIA cohorts in the world and six published scientific manuscripts to date. Most importantly it has provided essential new answers about disease presentation and short to medium-term prognosis. The initial study was leveraged into two subsequent studies also funded by CIHR: Biologically Based Outcomes Predictors in JIA (BBOP) and Linking Exercise, Activity, and Pathophysiology in Canadian children with Arthritis (LEAP). Continuation of this effort with a new registry can illuminate longer term prognosis for JIA patients. The rapidly changing landscape of available therapies necessitates maintenance and extension of the registry to elucidate the changing prognosis in different therapeutic eras, and to enable contemporary prognostic counseling to new patients and their families. In April 2015, The Arthritis Society provided an infrastructure award to continue, expand and strengthen a harmonized Canadian registry of patients with JIA, to support pediatric rheumatology research. This award has been enriched with other sources to include assessment of medication adverse events, thus providing the funding that will be used for this CAPRI national JIA registry. 2. GOALS AND PRINCIPLES The goal of the CAPRI JIA registry is to prospectively collect information on disease course, outcomes and medication adverse events among Canadian children with JIA. The registry will: 1. Provide answers about the expected disease outcomes and the risks of medication adverse events for patients and care providers. 2. Contribute to new insights about JIA and its treatment through yearly updates of registry findings and publication of scientific papers. 3. Allow Canadian researchers to answer their own research questions about JIA. 4. Allow comparison of JIA outcomes and treatments across Canada and with other jurisdictions, in support of quality improvement initiatives. The registry will operate following five principles: Universal: all children newly diagnosed with JIA across Canada will be eligible. Simple: the registry will require minimum training and time to collect information. High-Quality: the registry will emphasize quality over quantity of data and the quality of data will be continually monitored. Clinician-centered: the registry will ensure that physicians who follow children with JIA are engaged and see value from their contribution to the registry. Linkable: the registry will make provisions for future linkages to existing research and healthcare cohorts, to Statistics Canada data and to other databases. 3. METHODS 3.1 Registry oversight The registry will be managed through CAPRI. A registry committee of CAPRI has been established, with the following responsibilities: 1. Oversight of all registry functions. 2. Report to CAPRI executive. 3. Supervision of the registry coordinator. The registry committee consists of CAPRI members who volunteer for a 2-year renewable term. The group has elected a chair (Dr. Jaime Guzman) who will be the direct contact for the registry coordinator, organize teleconferences and provide reports to the chair of CAPRI. The registry committee chair will sit on the CAPRI executive committee. Funding from registry sponsors will come to a central registry account. The registry committee and its chair will be responsible for fund payments, as per agreed CAPRI budget. Financial accounting will be managed by the registry coordinator. The registry will be subject to the following reporting processes: 1. Annual report to registry sponsors including budget use and progress. 2. Bi-annual report to the CAPRI membership on progress, registry statistics, and budget. A copy of the bi-annual report will be sent to registry sponsors. 3. Annual research output report after the first year of registry operations. 4. Annual update on registry findings to be shared with families and care providers. 3.2 Set up of registry centres All CAPRI centres and pediatric rheumatology practices in Canada are eligible to participate in the registry. Participating sites will designate a registry site director for communication and management purposes. Each site will be responsible for patient enrollment, data entry, and maintenance of appropriate registry records for their site. The registry site director will manage their own site budget, and be required to provide annual budget records. The registry coordinator will assist each registry site in completing the following steps necessary for set up: 1. Submission of registry protocol for ethics review by the local ethics board and amendments as needed 2. Deciding on the logistics of patient recruitment and registration that best fit with the centre current practices and processes. 3. Deciding on the logistics of data collection that best fit their local practices and processes, including timelines for data submission and locking of the data. 4. Review and agree on the processes for data quality monitoring. 3.3 Patient recruitment and registration At the medical visit where a new diagnosis of JIA is made, the pediatric rheumatologist making the diagnosis will introduce the registry to the patient. The registry site director or delegate will then provide the family with full information about the registry and ask for their written consent. ReACCh-Out and LEAP participants will be asked to re-consent for the registry at their first regular visit. Registration includes three steps: 1. Review and signing of the consent form 2. Assignment of a unique registry identification number by an automated online system 3. Collection of initial registry data as described below 3.4 Data collection The registry will collect data from the pediatric rheumatologist caring for the child, and from the child and the child's parent or guardian. Data will be collected from the physician and families at registration followed by a minimum set of data at every subsequent clinic visit. Additional data once yearly at a visit close to the anniversary of the diagnosis will be collected from families. All data will be collected at clinic visits and there will be no visits booked specifically for registry purposes. The primary method of data collection from physicians will be direct entry online using a secure web site located at a Canadian academic centre, via computer or smart phone. The secondary method of data collection will be in paper forms for physicians who prefer that method. Data in paper forms will then be entered online by research assistants. The primary method of data collection from families will be in paper forms. The answers will be verified by research assistants and then entered online. The secondary method of data collection will be direct entry online for centres where existing infrastructure allows for direct entry by families at the time of the visit. 3.5 Protection of privacy and confidentiality All data collected will be handled in accordance with federal and provincial personal information legislation. Information that would allow identification of a child, such as name, date of birth and address will only be collected in the consent form. This information will be separate from registry information and will not be available in any online system. All subsequent data collection will have no personal identifying information, only the registry identification number. The de-identified registry information will be stored online in a dedicated RedCap server at a Canadian academic centre that complies with all encryption and audit regulatory requirements. As this is an ongoing registry de-identified electronic records will be kept indefinitely in the secure servers. There is a possibility in the future to have international collaborations to help with data analysis. In this case, data sent outside of Canada will not contain any personal identifying information and will be strictly de-identified. Any de-identified paper records used during the process of entering information in the registry will be kept under locked storage for ten years and then destroyed. They are to be used in case of need for confirmation of the veracity of the data for scientific publication purposes. 3.6 Data quality monitoring The continuous monitoring of data quality is an essential function of the registry and the major responsibility of the registry coordinator. The registry committee and its chair bear final accountability for the quality of the data entered in the registry. The following four complementary methods will ensure the data contained in the registry is complete and of the highest possible quality: 1. Quality control during data entry: Defines the automatic quality controls set up as part of data entry for each questionnaire or form. 2. Daily quality control by registry coordinator: Defines the daily activities of the registry coordinator to monitor data quality and actions to follow through on issues identified. 3. Quality control at periodic centre audits: Defines indications for quality audits, their periodicity and how their results are assessed and followed through. 4. Monthly update on quality control to registry chair: defines the components of the monthly quality update, how it is prepared and how it is assessed by the chair. 3.7 Access to data To assist healthcare provision: Patients and their physicians will have access to their data to obtain estimates of expected outcomes and risks of side effects based on analyses of registry data. To answer research questions: CAPRI and non-researchers may request access to registry data to answer research questions. To assist planning and program development: Healthcare organizations, registry sponsors, health authorities and ministries of health services, may request access to summary statistics or de-identified group data for use in knowledge translation activities or to assist in their planning of programs and delivery of care. More... »

URL

https://clinicaltrials.gov/show/NCT03245801

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Juvenile Idiopathic Arthritis (JIA) is a disorder of unknown cause characterized by chronic inflammation of the joints and other organs. It affects about 1 in a 1000 Canadian children and if untreated it can produce lifelong disability. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) includes most pediatric rheumatologists in Canada. They have successfully collaborated for the past 10 years producing groundbreaking research on the modern course and outcomes of JIA. CAPRI proposes an ongoing universal registry of Canadian children with JIA that will collect longitudinal data on disease course, outcomes and adverse events to inform healthcare decisions and to gain new insights into the disease and its treatment.\n\nDetailed Description\n1. BACKGROUND JIA includes all chronic arthritis of unknown cause starting before the age of 16. JIA is the most common rheumatic disease of childhood, affecting approximately 1 in 1,000 Canadian children. Despite trends to more favorable outcomes, JIA continues to have disabling sequelae that reduce mobility, quality of life and future productivity, affecting the child, their families and society as a whole. After a diagnosis of JIA, families have many questions about the prognosis of their child, treatments that may be required and their potential side-effects. Despite numerous studies, our ability to answer these questions remains limited. International League of Associations for Rheumatology (ILAR) criteria classify children with JIA into seven categories based on clinical manifestations and laboratory tests. Current practice recommendations propose use of medications tailored according to JIA category or according to treatment groups defined by number of joints affected and features of poor prognosis. In general, initial treatment with intraarticular corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for JIA affecting a few joints; while methotrexate and biologic agents are recommended when many joints are affected and for children with features of poor prognosis. CAPRI is the collaborative network of all pediatric rheumatology investigators across Canada, with an outstanding track record of successful collaboration in a number of research projects. Since 2005 CAPRI investigators have worked on a project called ReACCH-Out, a team grant funded by the Canadian Institutes of Health Research (CIHR) to study the impact of arthritis on Canadian children. CAPRI developed a robust web-based longitudinal data base and enrolled 1,500 newly diagnosed children with JIA during a five year period. This study has resulted in one of the largest longitudinal JIA cohorts in the world and six published scientific manuscripts to date. Most importantly it has provided essential new answers about disease presentation and short to medium-term prognosis. The initial study was leveraged into two subsequent studies also funded by CIHR: Biologically Based Outcomes Predictors in JIA (BBOP) and Linking Exercise, Activity, and Pathophysiology in Canadian children with Arthritis (LEAP). Continuation of this effort with a new registry can illuminate longer term prognosis for JIA patients. The rapidly changing landscape of available therapies necessitates maintenance and extension of the registry to elucidate the changing prognosis in different therapeutic eras, and to enable contemporary prognostic counseling to new patients and their families. In April 2015, The Arthritis Society provided an infrastructure award to continue, expand and strengthen a harmonized Canadian registry of patients with JIA, to support pediatric rheumatology research. This award has been enriched with other sources to include assessment of medication adverse events, thus providing the funding that will be used for this CAPRI national JIA registry. 2. GOALS AND PRINCIPLES The goal of the CAPRI JIA registry is to prospectively collect information on disease course, outcomes and medication adverse events among Canadian children with JIA. The registry will: 1. Provide answers about the expected disease outcomes and the risks of medication adverse events for patients and care providers. 2. Contribute to new insights about JIA and its treatment through yearly updates of registry findings and publication of scientific papers. 3. Allow Canadian researchers to answer their own research questions about JIA. 4. Allow comparison of JIA outcomes and treatments across Canada and with other jurisdictions, in support of quality improvement initiatives. The registry will operate following five principles: Universal: all children newly diagnosed with JIA across Canada will be eligible. Simple: the registry will require minimum training and time to collect information. High-Quality: the registry will emphasize quality over quantity of data and the quality of data will be continually monitored. Clinician-centered: the registry will ensure that physicians who follow children with JIA are engaged and see value from their contribution to the registry. Linkable: the registry will make provisions for future linkages to existing research and healthcare cohorts, to Statistics Canada data and to other databases. 3. METHODS 3.1 Registry oversight The registry will be managed through CAPRI. A registry committee of CAPRI has been established, with the following responsibilities: 1. Oversight of all registry functions. 2. Report to CAPRI executive. 3. Supervision of the registry coordinator. The registry committee consists of CAPRI members who volunteer for a 2-year renewable term. The group has elected a chair (Dr. Jaime Guzman) who will be the direct contact for the registry coordinator, organize teleconferences and provide reports to the chair of CAPRI. The registry committee chair will sit on the CAPRI executive committee. Funding from registry sponsors will come to a central registry account. The registry committee and its chair will be responsible for fund payments, as per agreed CAPRI budget. Financial accounting will be managed by the registry coordinator. The registry will be subject to the following reporting processes: 1. Annual report to registry sponsors including budget use and progress. 2. Bi-annual report to the CAPRI membership on progress, registry statistics, and budget. A copy of the bi-annual report will be sent to registry sponsors. 3. Annual research output report after the first year of registry operations. 4. Annual update on registry findings to be shared with families and care providers. 3.2 Set up of registry centres All CAPRI centres and pediatric rheumatology practices in Canada are eligible to participate in the registry. Participating sites will designate a registry site director for communication and management purposes. Each site will be responsible for patient enrollment, data entry, and maintenance of appropriate registry records for their site. The registry site director will manage their own site budget, and be required to provide annual budget records. The registry coordinator will assist each registry site in completing the following steps necessary for set up: 1. Submission of registry protocol for ethics review by the local ethics board and amendments as needed 2. Deciding on the logistics of patient recruitment and registration that best fit with the centre current practices and processes. 3. Deciding on the logistics of data collection that best fit their local practices and processes, including timelines for data submission and locking of the data. 4. Review and agree on the processes for data quality monitoring. 3.3 Patient recruitment and registration At the medical visit where a new diagnosis of JIA is made, the pediatric rheumatologist making the diagnosis will introduce the registry to the patient. The registry site director or delegate will then provide the family with full information about the registry and ask for their written consent. ReACCh-Out and LEAP participants will be asked to re-consent for the registry at their first regular visit. Registration includes three steps: 1. Review and signing of the consent form 2. Assignment of a unique registry identification number by an automated online system 3. Collection of initial registry data as described below 3.4 Data collection The registry will collect data from the pediatric rheumatologist caring for the child, and from the child and the child's parent or guardian. Data will be collected from the physician and families at registration followed by a minimum set of data at every subsequent clinic visit. Additional data once yearly at a visit close to the anniversary of the diagnosis will be collected from families. All data will be collected at clinic visits and there will be no visits booked specifically for registry purposes. The primary method of data collection from physicians will be direct entry online using a secure web site located at a Canadian academic centre, via computer or smart phone. The secondary method of data collection will be in paper forms for physicians who prefer that method. Data in paper forms will then be entered online by research assistants. The primary method of data collection from families will be in paper forms. The answers will be verified by research assistants and then entered online. The secondary method of data collection will be direct entry online for centres where existing infrastructure allows for direct entry by families at the time of the visit. 3.5 Protection of privacy and confidentiality All data collected will be handled in accordance with federal and provincial personal information legislation. Information that would allow identification of a child, such as name, date of birth and address will only be collected in the consent form. This information will be separate from registry information and will not be available in any online system. All subsequent data collection will have no personal identifying information, only the registry identification number. The de-identified registry information will be stored online in a dedicated RedCap server at a Canadian academic centre that complies with all encryption and audit regulatory requirements. As this is an ongoing registry de-identified electronic records will be kept indefinitely in the secure servers. There is a possibility in the future to have international collaborations to help with data analysis. In this case, data sent outside of Canada will not contain any personal identifying information and will be strictly de-identified. Any de-identified paper records used during the process of entering information in the registry will be kept under locked storage for ten years and then destroyed. They are to be used in case of need for confirmation of the veracity of the data for scientific publication purposes. 3.6 Data quality monitoring The continuous monitoring of data quality is an essential function of the registry and the major responsibility of the registry coordinator. The registry committee and its chair bear final accountability for the quality of the data entered in the registry. The following four complementary methods will ensure the data contained in the registry is complete and of the highest possible quality: 1. Quality control during data entry: Defines the automatic quality controls set up as part of data entry for each questionnaire or form. 2. Daily quality control by registry coordinator: Defines the daily activities of the registry coordinator to monitor data quality and actions to follow through on issues identified. 3. Quality control at periodic centre audits: Defines indications for quality audits, their periodicity and how their results are assessed and followed through. 4. Monthly update on quality control to registry chair: defines the components of the monthly quality update, how it is prepared and how it is assessed by the chair. 3.7 Access to data To assist healthcare provision: Patients and their physicians will have access to their data to obtain estimates of expected outcomes and risks of side effects based on analyses of registry data. To answer research questions: CAPRI and non-researchers may request access to registry data to answer research questions. To assist planning and program development: Healthcare organizations, registry sponsors, health authorities and ministries of health services, may request access to summary statistics or de-identified group data for use in knowledge translation activities or to assist in their planning of programs and delivery of care.", 
    "endDate": "2026-02-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03245801", 
    "keywords": [
      "canadian", 
      "pediatric rheumatology", 
      "arthritis", 
      "Juvenile Arthritis", 
      "disorder", 
      "chronic inflammation", 
      "joint", 
      "organ", 
      "Canadian child", 
      "disability", 
      "rheumatologist", 
      "Canada", 
      "modern", 
      "registry", 
      "longitudinal data", 
      "disease course", 
      "adverse event", 
      "healthcare decision", 
      "disease", 
      "juvenile", 
      "chronic arthritis", 
      "age", 
      "rheumatic disease", 
      "childhood", 
      "trend", 
      "favorable outcome", 
      "sequela", 
      "mobility", 
      "life", 
      "future productivity", 
      "child", 
      "family", 
      "society", 
      "diagnosis", 
      "prognosis", 
      "potential side effect", 
      "Numerous study", 
      "International", 
      "criterion", 
      "category", 
      "clinical manifestation", 
      "laboratory test", 
      "practice recommendation", 
      "medication", 
      "treatment group", 
      "feature", 
      "poor prognosis", 
      "initial treatment", 
      "corticosteroid", 
      "nonsteroidal anti-inflammatory drug", 
      "methotrexate", 
      "biologic agent", 
      "collaborative network", 
      "outstanding track record", 
      "successful collaboration", 
      "research project", 
      "team grant", 
      "Canadian Institutes of Health Research", 
      "diagnosed child", 
      "period", 
      "world", 
      "scientific manuscript", 
      "date", 
      "disease presentation", 
      "medium term", 
      "initial study", 
      "exercise", 
      "leap", 
      "continuation", 
      "illuminate", 
      "long-term prognosis", 
      "arthritis patient", 
      "landscape", 
      "available therapy", 
      "extension", 
      "therapeutic", 
      "prognostic", 
      "patient", 
      "April", 
      "infrastructure award", 
      "assessment", 
      "principle", 
      "Provide", 
      "disease outcome", 
      "risk", 
      "care provider", 
      "Contribute", 
      "update", 
      "publication", 
      "scientific paper", 
      "Canadian researcher", 
      "research question", 
      "comparison", 
      "jurisdiction", 
      "quality improvement initiative", 
      "high quality", 
      "quantity", 
      "physician", 
      "contribution", 
      "provision", 
      "linkage", 
      "cohort", 
      "Statistics Canada", 
      "database", 
      "method", 
      "oversight", 
      "committee", 
      "responsibility", 
      "Organization and Administration", 
      "coordinator", 
      "volunteer", 
      "chair", 
      "direct contact", 
      "telecommunication", 
      "payment", 
      "budget", 
      "progress", 
      "statistic", 
      "copy", 
      "research output", 
      "operation", 
      "site director", 
      "communication", 
      "management", 
      "patient enrollment", 
      "data entry", 
      "annual budget", 
      "submission", 
      "ethic review", 
      "ethic", 
      "amendment", 
      "Patient Selection", 
      "registration", 
      "current practice", 
      "Data Collection", 
      "local practice", 
      "timeline", 
      "data submission", 
      "review", 
      "Research Design", 
      "medical visit", 
      "delegate", 
      "full information", 
      "consent", 
      "regular visit", 
      "signing", 
      "assignment", 
      "online system", 
      "collection", 
      "registry data", 
      "parent", 
      "guardian", 
      "minimum set", 
      "clinic", 
      "visit", 
      "Anniversary and Special Event", 
      "Ambulatory Care", 
      "primary method", 
      "direct entry", 
      "web site", 
      "academic center", 
      "computer", 
      "smart phone", 
      "paper form", 
      "online", 
      "research assistant", 
      "infrastructure", 
      "protection", 
      "privacy", 
      "confidentiality", 
      "accordance", 
      "personal information", 
      "name", 
      "Parturition", 
      "consent form", 
      "server", 
      "complies", 
      "regulatory requirement", 
      "electronic record", 
      "possibility", 
      "international collaboration", 
      "Statistic as Topic", 
      "paper record", 
      "storage", 
      "confirmation", 
      "veracity", 
      "scientific publication", 
      "essential function", 
      "major responsibility", 
      "complementary method", 
      "high possible quality", 
      "quality control", 
      "Define", 
      "questionnaire", 
      "audit", 
      "indication", 
      "periodicity", 
      "component", 
      "access", 
      "healthcare provision", 
      "expected outcome", 
      "side effect", 
      "request", 
      "program development", 
      "healthcare organization", 
      "health authority", 
      "ministry", 
      "health service", 
      "summary statistic", 
      "identified group", 
      "knowledge translation activity", 
      "delivery", 
      "care"
    ], 
    "name": "The Canadian Alliance of Pediatric Rheumatology Investigators National Juvenile Idiopathic Arthritis Registry", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03245801"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00025.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.17091.3e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.17089.37", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.86715.3d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.21613.37", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.25055.37", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.63984.30", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.22072.35", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.475621.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413571.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.14848.31", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414148.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.42327.30", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414137.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.422356.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412745.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.25073.33", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412271.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-02-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1053/berh.2002.0233", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010241078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.20044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018529258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.20460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020316437"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2014-207164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022718565"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.24539", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024248266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00296-014-3085-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027958988", 
          "https://doi.org/10.1007/s00296-014-3085-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/keh620", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041103473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2014-205372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043910366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clim.2011.10.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047942473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.100083", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071542181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076634133", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076796798", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03245801"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03245801'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03245801'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03245801'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03245801'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      16 PREDICATES      256 URIs      222 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03245801 schema:about anzsrc-for:3177
2 schema:description Juvenile Idiopathic Arthritis (JIA) is a disorder of unknown cause characterized by chronic inflammation of the joints and other organs. It affects about 1 in a 1000 Canadian children and if untreated it can produce lifelong disability. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) includes most pediatric rheumatologists in Canada. They have successfully collaborated for the past 10 years producing groundbreaking research on the modern course and outcomes of JIA. CAPRI proposes an ongoing universal registry of Canadian children with JIA that will collect longitudinal data on disease course, outcomes and adverse events to inform healthcare decisions and to gain new insights into the disease and its treatment. Detailed Description 1. BACKGROUND JIA includes all chronic arthritis of unknown cause starting before the age of 16. JIA is the most common rheumatic disease of childhood, affecting approximately 1 in 1,000 Canadian children. Despite trends to more favorable outcomes, JIA continues to have disabling sequelae that reduce mobility, quality of life and future productivity, affecting the child, their families and society as a whole. After a diagnosis of JIA, families have many questions about the prognosis of their child, treatments that may be required and their potential side-effects. Despite numerous studies, our ability to answer these questions remains limited. International League of Associations for Rheumatology (ILAR) criteria classify children with JIA into seven categories based on clinical manifestations and laboratory tests. Current practice recommendations propose use of medications tailored according to JIA category or according to treatment groups defined by number of joints affected and features of poor prognosis. In general, initial treatment with intraarticular corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for JIA affecting a few joints; while methotrexate and biologic agents are recommended when many joints are affected and for children with features of poor prognosis. CAPRI is the collaborative network of all pediatric rheumatology investigators across Canada, with an outstanding track record of successful collaboration in a number of research projects. Since 2005 CAPRI investigators have worked on a project called ReACCH-Out, a team grant funded by the Canadian Institutes of Health Research (CIHR) to study the impact of arthritis on Canadian children. CAPRI developed a robust web-based longitudinal data base and enrolled 1,500 newly diagnosed children with JIA during a five year period. This study has resulted in one of the largest longitudinal JIA cohorts in the world and six published scientific manuscripts to date. Most importantly it has provided essential new answers about disease presentation and short to medium-term prognosis. The initial study was leveraged into two subsequent studies also funded by CIHR: Biologically Based Outcomes Predictors in JIA (BBOP) and Linking Exercise, Activity, and Pathophysiology in Canadian children with Arthritis (LEAP). Continuation of this effort with a new registry can illuminate longer term prognosis for JIA patients. The rapidly changing landscape of available therapies necessitates maintenance and extension of the registry to elucidate the changing prognosis in different therapeutic eras, and to enable contemporary prognostic counseling to new patients and their families. In April 2015, The Arthritis Society provided an infrastructure award to continue, expand and strengthen a harmonized Canadian registry of patients with JIA, to support pediatric rheumatology research. This award has been enriched with other sources to include assessment of medication adverse events, thus providing the funding that will be used for this CAPRI national JIA registry. 2. GOALS AND PRINCIPLES The goal of the CAPRI JIA registry is to prospectively collect information on disease course, outcomes and medication adverse events among Canadian children with JIA. The registry will: 1. Provide answers about the expected disease outcomes and the risks of medication adverse events for patients and care providers. 2. Contribute to new insights about JIA and its treatment through yearly updates of registry findings and publication of scientific papers. 3. Allow Canadian researchers to answer their own research questions about JIA. 4. Allow comparison of JIA outcomes and treatments across Canada and with other jurisdictions, in support of quality improvement initiatives. The registry will operate following five principles: Universal: all children newly diagnosed with JIA across Canada will be eligible. Simple: the registry will require minimum training and time to collect information. High-Quality: the registry will emphasize quality over quantity of data and the quality of data will be continually monitored. Clinician-centered: the registry will ensure that physicians who follow children with JIA are engaged and see value from their contribution to the registry. Linkable: the registry will make provisions for future linkages to existing research and healthcare cohorts, to Statistics Canada data and to other databases. 3. METHODS 3.1 Registry oversight The registry will be managed through CAPRI. A registry committee of CAPRI has been established, with the following responsibilities: 1. Oversight of all registry functions. 2. Report to CAPRI executive. 3. Supervision of the registry coordinator. The registry committee consists of CAPRI members who volunteer for a 2-year renewable term. The group has elected a chair (Dr. Jaime Guzman) who will be the direct contact for the registry coordinator, organize teleconferences and provide reports to the chair of CAPRI. The registry committee chair will sit on the CAPRI executive committee. Funding from registry sponsors will come to a central registry account. The registry committee and its chair will be responsible for fund payments, as per agreed CAPRI budget. Financial accounting will be managed by the registry coordinator. The registry will be subject to the following reporting processes: 1. Annual report to registry sponsors including budget use and progress. 2. Bi-annual report to the CAPRI membership on progress, registry statistics, and budget. A copy of the bi-annual report will be sent to registry sponsors. 3. Annual research output report after the first year of registry operations. 4. Annual update on registry findings to be shared with families and care providers. 3.2 Set up of registry centres All CAPRI centres and pediatric rheumatology practices in Canada are eligible to participate in the registry. Participating sites will designate a registry site director for communication and management purposes. Each site will be responsible for patient enrollment, data entry, and maintenance of appropriate registry records for their site. The registry site director will manage their own site budget, and be required to provide annual budget records. The registry coordinator will assist each registry site in completing the following steps necessary for set up: 1. Submission of registry protocol for ethics review by the local ethics board and amendments as needed 2. Deciding on the logistics of patient recruitment and registration that best fit with the centre current practices and processes. 3. Deciding on the logistics of data collection that best fit their local practices and processes, including timelines for data submission and locking of the data. 4. Review and agree on the processes for data quality monitoring. 3.3 Patient recruitment and registration At the medical visit where a new diagnosis of JIA is made, the pediatric rheumatologist making the diagnosis will introduce the registry to the patient. The registry site director or delegate will then provide the family with full information about the registry and ask for their written consent. ReACCh-Out and LEAP participants will be asked to re-consent for the registry at their first regular visit. Registration includes three steps: 1. Review and signing of the consent form 2. Assignment of a unique registry identification number by an automated online system 3. Collection of initial registry data as described below 3.4 Data collection The registry will collect data from the pediatric rheumatologist caring for the child, and from the child and the child's parent or guardian. Data will be collected from the physician and families at registration followed by a minimum set of data at every subsequent clinic visit. Additional data once yearly at a visit close to the anniversary of the diagnosis will be collected from families. All data will be collected at clinic visits and there will be no visits booked specifically for registry purposes. The primary method of data collection from physicians will be direct entry online using a secure web site located at a Canadian academic centre, via computer or smart phone. The secondary method of data collection will be in paper forms for physicians who prefer that method. Data in paper forms will then be entered online by research assistants. The primary method of data collection from families will be in paper forms. The answers will be verified by research assistants and then entered online. The secondary method of data collection will be direct entry online for centres where existing infrastructure allows for direct entry by families at the time of the visit. 3.5 Protection of privacy and confidentiality All data collected will be handled in accordance with federal and provincial personal information legislation. Information that would allow identification of a child, such as name, date of birth and address will only be collected in the consent form. This information will be separate from registry information and will not be available in any online system. All subsequent data collection will have no personal identifying information, only the registry identification number. The de-identified registry information will be stored online in a dedicated RedCap server at a Canadian academic centre that complies with all encryption and audit regulatory requirements. As this is an ongoing registry de-identified electronic records will be kept indefinitely in the secure servers. There is a possibility in the future to have international collaborations to help with data analysis. In this case, data sent outside of Canada will not contain any personal identifying information and will be strictly de-identified. Any de-identified paper records used during the process of entering information in the registry will be kept under locked storage for ten years and then destroyed. They are to be used in case of need for confirmation of the veracity of the data for scientific publication purposes. 3.6 Data quality monitoring The continuous monitoring of data quality is an essential function of the registry and the major responsibility of the registry coordinator. The registry committee and its chair bear final accountability for the quality of the data entered in the registry. The following four complementary methods will ensure the data contained in the registry is complete and of the highest possible quality: 1. Quality control during data entry: Defines the automatic quality controls set up as part of data entry for each questionnaire or form. 2. Daily quality control by registry coordinator: Defines the daily activities of the registry coordinator to monitor data quality and actions to follow through on issues identified. 3. Quality control at periodic centre audits: Defines indications for quality audits, their periodicity and how their results are assessed and followed through. 4. Monthly update on quality control to registry chair: defines the components of the monthly quality update, how it is prepared and how it is assessed by the chair. 3.7 Access to data To assist healthcare provision: Patients and their physicians will have access to their data to obtain estimates of expected outcomes and risks of side effects based on analyses of registry data. To answer research questions: CAPRI and non-researchers may request access to registry data to answer research questions. To assist planning and program development: Healthcare organizations, registry sponsors, health authorities and ministries of health services, may request access to summary statistics or de-identified group data for use in knowledge translation activities or to assist in their planning of programs and delivery of care.
3 schema:endDate 2026-02-01T00:00:00Z
4 schema:keywords Ambulatory Care
5 Anniversary and Special Event
6 April
7 Canada
8 Canadian Institutes of Health Research
9 Canadian child
10 Canadian researcher
11 Contribute
12 Data Collection
13 Define
14 International
15 Juvenile Arthritis
16 Numerous study
17 Organization and Administration
18 Parturition
19 Patient Selection
20 Provide
21 Research Design
22 Statistic as Topic
23 Statistics Canada
24 academic center
25 access
26 accordance
27 adverse event
28 age
29 amendment
30 annual budget
31 arthritis
32 arthritis patient
33 assessment
34 assignment
35 audit
36 available therapy
37 biologic agent
38 budget
39 canadian
40 care
41 care provider
42 category
43 chair
44 child
45 childhood
46 chronic arthritis
47 chronic inflammation
48 clinic
49 clinical manifestation
50 cohort
51 collaborative network
52 collection
53 committee
54 communication
55 comparison
56 complementary method
57 complies
58 component
59 computer
60 confidentiality
61 confirmation
62 consent
63 consent form
64 continuation
65 contribution
66 coordinator
67 copy
68 corticosteroid
69 criterion
70 current practice
71 data entry
72 data submission
73 database
74 date
75 delegate
76 delivery
77 diagnosed child
78 diagnosis
79 direct contact
80 direct entry
81 disability
82 disease
83 disease course
84 disease outcome
85 disease presentation
86 disorder
87 electronic record
88 essential function
89 ethic
90 ethic review
91 exercise
92 expected outcome
93 extension
94 family
95 favorable outcome
96 feature
97 full information
98 future productivity
99 guardian
100 health authority
101 health service
102 healthcare decision
103 healthcare organization
104 healthcare provision
105 high possible quality
106 high quality
107 identified group
108 illuminate
109 indication
110 infrastructure
111 infrastructure award
112 initial study
113 initial treatment
114 international collaboration
115 joint
116 jurisdiction
117 juvenile
118 knowledge translation activity
119 laboratory test
120 landscape
121 leap
122 life
123 linkage
124 local practice
125 long-term prognosis
126 longitudinal data
127 major responsibility
128 management
129 medical visit
130 medication
131 medium term
132 method
133 methotrexate
134 minimum set
135 ministry
136 mobility
137 modern
138 name
139 nonsteroidal anti-inflammatory drug
140 online
141 online system
142 operation
143 organ
144 outstanding track record
145 oversight
146 paper form
147 paper record
148 parent
149 patient
150 patient enrollment
151 payment
152 pediatric rheumatology
153 period
154 periodicity
155 personal information
156 physician
157 poor prognosis
158 possibility
159 potential side effect
160 practice recommendation
161 primary method
162 principle
163 privacy
164 prognosis
165 prognostic
166 program development
167 progress
168 protection
169 provision
170 publication
171 quality control
172 quality improvement initiative
173 quantity
174 questionnaire
175 registration
176 registry
177 registry data
178 regular visit
179 regulatory requirement
180 request
181 research assistant
182 research output
183 research project
184 research question
185 responsibility
186 review
187 rheumatic disease
188 rheumatologist
189 risk
190 scientific manuscript
191 scientific paper
192 scientific publication
193 sequela
194 server
195 side effect
196 signing
197 site director
198 smart phone
199 society
200 statistic
201 storage
202 submission
203 successful collaboration
204 summary statistic
205 team grant
206 telecommunication
207 therapeutic
208 timeline
209 treatment group
210 trend
211 update
212 veracity
213 visit
214 volunteer
215 web site
216 world
217 schema:name The Canadian Alliance of Pediatric Rheumatology Investigators National Juvenile Idiopathic Arthritis Registry
218 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03245801
219 schema:sdDatePublished 2019-03-07T15:27
220 schema:sdLicense https://scigraph.springernature.com/explorer/license/
221 schema:sdPublisher N7fe7fb231b5d4778b18c9e9ee5e9023a
222 schema:sponsor https://www.grid.ac/institutes/grid.14848.31
223 https://www.grid.ac/institutes/grid.17089.37
224 https://www.grid.ac/institutes/grid.17091.3e
225 https://www.grid.ac/institutes/grid.21613.37
226 https://www.grid.ac/institutes/grid.22072.35
227 https://www.grid.ac/institutes/grid.25055.37
228 https://www.grid.ac/institutes/grid.25073.33
229 https://www.grid.ac/institutes/grid.412271.3
230 https://www.grid.ac/institutes/grid.412745.1
231 https://www.grid.ac/institutes/grid.413571.5
232 https://www.grid.ac/institutes/grid.414137.4
233 https://www.grid.ac/institutes/grid.414148.c
234 https://www.grid.ac/institutes/grid.422356.4
235 https://www.grid.ac/institutes/grid.42327.30
236 https://www.grid.ac/institutes/grid.475621.3
237 https://www.grid.ac/institutes/grid.63984.30
238 https://www.grid.ac/institutes/grid.86715.3d
239 schema:startDate 2017-02-01T00:00:00Z
240 schema:subjectOf sg:pub.10.1007/s00296-014-3085-0
241 https://app.dimensions.ai/details/publication/pub.1076634133
242 https://app.dimensions.ai/details/publication/pub.1076796798
243 https://doi.org/10.1002/acr.20044
244 https://doi.org/10.1002/acr.20460
245 https://doi.org/10.1002/art.24539
246 https://doi.org/10.1016/j.clim.2011.10.003
247 https://doi.org/10.1053/berh.2002.0233
248 https://doi.org/10.1093/rheumatology/keh620
249 https://doi.org/10.1136/annrheumdis-2014-205372
250 https://doi.org/10.1136/annrheumdis-2014-207164
251 https://doi.org/10.3899/jrheum.100083
252 schema:url https://clinicaltrials.gov/show/NCT03245801
253 sgo:license sg:explorer/license/
254 sgo:sdDataset clinical_trials
255 rdf:type schema:MedicalStudy
256 N7fe7fb231b5d4778b18c9e9ee5e9023a schema:name Springer Nature - SN SciGraph project
257 rdf:type schema:Organization
258 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
259 rdf:type schema:DefinedTerm
260 sg:pub.10.1007/s00296-014-3085-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027958988
261 https://doi.org/10.1007/s00296-014-3085-0
262 rdf:type schema:CreativeWork
263 https://app.dimensions.ai/details/publication/pub.1076634133 schema:CreativeWork
264 https://app.dimensions.ai/details/publication/pub.1076796798 schema:CreativeWork
265 https://doi.org/10.1002/acr.20044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018529258
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1002/acr.20460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020316437
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1002/art.24539 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024248266
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1016/j.clim.2011.10.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047942473
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1053/berh.2002.0233 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010241078
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1093/rheumatology/keh620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041103473
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1136/annrheumdis-2014-205372 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043910366
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1136/annrheumdis-2014-207164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022718565
280 rdf:type schema:CreativeWork
281 https://doi.org/10.3899/jrheum.100083 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071542181
282 rdf:type schema:CreativeWork
283 https://www.grid.ac/institutes/grid.14848.31 schema:Organization
284 https://www.grid.ac/institutes/grid.17089.37 schema:Organization
285 https://www.grid.ac/institutes/grid.17091.3e schema:Organization
286 https://www.grid.ac/institutes/grid.21613.37 schema:Organization
287 https://www.grid.ac/institutes/grid.22072.35 schema:Organization
288 https://www.grid.ac/institutes/grid.25055.37 schema:Organization
289 https://www.grid.ac/institutes/grid.25073.33 schema:Organization
290 https://www.grid.ac/institutes/grid.412271.3 schema:Organization
291 https://www.grid.ac/institutes/grid.412745.1 schema:Organization
292 https://www.grid.ac/institutes/grid.413571.5 schema:Organization
293 https://www.grid.ac/institutes/grid.414137.4 schema:Organization
294 https://www.grid.ac/institutes/grid.414148.c schema:Organization
295 https://www.grid.ac/institutes/grid.422356.4 schema:Organization
296 https://www.grid.ac/institutes/grid.42327.30 schema:Organization
297 https://www.grid.ac/institutes/grid.475621.3 schema:Organization
298 https://www.grid.ac/institutes/grid.63984.30 schema:Organization
299 https://www.grid.ac/institutes/grid.86715.3d schema:Organization
 




Preview window. Press ESC to close (or click here)


...